Risankizumab for The Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from The Czech Republic
media
posted on 2021-05-28, 14:42 authored by Adis journals on behalf of:, Spyridon Gkalpakiotis, Petra Cetkovska, Petr Arenberger, Tomas Dolezal, Monika Arenbergerova, Barbora Velackova, Jorga Fialova, Martina Kojanova, and the BIOREP study group<p><strong>Article full
text</strong></p>
<p> </p>
<p><br></p>
<p> </p>
<p>The above summary slide represents
the opinions of the authors. For a full list of declarations, including funding
and author disclosure statements, please see the full text online (see “read
the peer-reviewed publication” opposite). </p>
<p>© The authors, CC-BY-NC 2021.</p>
History
Related Materials
- 1.
- 2.
